Literature DB >> 33745271

Synergistic Action of Diclofenac with Endotoxin-Mediated Inflammation Exacerbates Intestinal Injury in Vitro.

Wen Li Kelly Chen1, Emily Suter1, Hikaru Miyazaki1, Jason Velazquez1, Douglas A Lauffenburger1, Linda G Griffith1,2,3, Rebecca L Carrier4.   

Abstract

Intestinal homeostasis is tightly regulated by the orchestrated actions of a multitude of cell types, including enterocytes, goblet cells, and immune cells. Disruption of intestinal barrier function can increase susceptibility to pathogen invasion and destabilize commensal microbial-epithelial-immune interaction, manifesting in various intestinal and systemic pathologies. However, a quantitative understanding of how these cell types communicate and collectively contribute to tissue function in health and disease is lacking. Here, we utilized a human intestinal epithelial-dendritic cell model and multivariate analysis of secreted factors to investigate the cellular crosstalk in response to physiological and/or pathological cues (e.g., endotoxin, nonsteroidal anti-inflammation drug (NSAID)). Specifically, we demonstrated that treatment with diclofenac (DCF), an NSAID commonly used to treat inflammation associated with acute infection and other conditions, globally suppressed cytokine secretion when dosed in isolation. However, the disruption of barrier function induced by DCF allowed for luminal lipopolysaccharide (LPS) translocation and activation of resident immune cells that overrode the anti-inflammatory influence of DCF. DCF-facilitated inflammation in the presence of LPS was in part mediated by upregulation of macrophage migration inhibitory factor (MIF), an important regulator of innate immunity. However, while neutralization of MIF activity normalized inflammation, it did not lead to intestinal healing. Our data suggest that systems-wide suppression of inflammation alone is insufficient to achieve mucosal healing, especially in the presence of DCF, the target of which, the COX-prostaglandin pathway, is central to mucosal homeostasis. Indeed, DCF removal postinjury enabled partial recovery of intestinal epithelium functions, and this recovery phase was associated with upregulation of a subset of cytokines and chemokines, implicating their potential contribution to intestinal healing. The results highlight the utility of an intestinal model capturing immune function, coupled with multivariate analysis, in understanding molecular mechanisms governing response to microbial factors, supporting application in studying host-pathogen interactions.

Entities:  

Keywords:  NSAIDs; bacterial translocation; inflammation; leaky gut; macrophage migration inhibitory factor (MIF); small intestine

Mesh:

Substances:

Year:  2021        PMID: 33745271      PMCID: PMC9109718          DOI: 10.1021/acsinfecdis.0c00762

Source DB:  PubMed          Journal:  ACS Infect Dis        ISSN: 2373-8227            Impact factor:   5.578


  39 in total

Review 1.  The intestinal epithelial barrier: a therapeutic target?

Authors:  Matthew A Odenwald; Jerrold R Turner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-11-16       Impact factor: 46.802

2.  Resistance to experimental colitis depends on cytoprotective heat shock proteins in macrophage migration inhibitory factor null mice.

Authors:  Tatsuya Ohkawara; Jun Nishihira; Yoh Ishiguro; Eiji Otsubo; Koichi Nagai; Hiroshi Takeda; Mototsugu Kato; Takashi Yoshiki; Toshihiko Iwanaga; Masahiro Asaka
Journal:  Immunol Lett       Date:  2006-09-26       Impact factor: 3.685

Review 3.  New therapeutic target in inflammatory disease: macrophage migration inhibitory factor.

Authors:  E F Morand
Journal:  Intern Med J       Date:  2005-07       Impact factor: 2.048

Review 4.  Macrophage Migration Inhibitory Factor (MIF): Biological Activities and Relation with Cancer.

Authors:  Camila Cristina Guimarães Nobre; Josélio Maria Galvão de Araújo; Thales Allyrio Araújo de Medeiros Fernandes; Ricardo Ney Oliveira Cobucci; Daniel Carlos Ferreira Lanza; Vânia Sousa Andrade; José Veríssimo Fernandes
Journal:  Pathol Oncol Res       Date:  2016-10-23       Impact factor: 3.201

5.  Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders.

Authors:  Elaine Y Hsiao; Sara W McBride; Sophia Hsien; Gil Sharon; Embriette R Hyde; Tyler McCue; Julian A Codelli; Janet Chow; Sarah E Reisman; Joseph F Petrosino; Paul H Patterson; Sarkis K Mazmanian
Journal:  Cell       Date:  2013-12-05       Impact factor: 41.582

6.  Roles of endogenous prostaglandins and cyclooxygenase isozymes in healing of indomethacin-induced small intestinal lesions in rats.

Authors:  Ryo Hatazawa; Ryoko Ohno; Mayu Tanigami; Akiko Tanaka; Koji Takeuchi
Journal:  J Pharmacol Exp Ther       Date:  2006-05-12       Impact factor: 4.030

7.  Diclofenac delays healing of gastroduodenal mucosal lesions. Double-blind, placebo-controlled endoscopic study in healthy volunteers.

Authors:  P Stadler; D Armstrong; D Margalith; E Saraga; M Stolte; P Lualdi; G Mautone; A L Blum
Journal:  Dig Dis Sci       Date:  1991-05       Impact factor: 3.199

Review 8.  Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation?

Authors:  Hiroshi Fukui
Journal:  Inflamm Intest Dis       Date:  2016-07-20

9.  Multi-scale in vivo systems analysis reveals the influence of immune cells on TNF-α-induced apoptosis in the intestinal epithelium.

Authors:  Ken S Lau; Virna Cortez-Retamozo; Sarah R Philips; Mikael J Pittet; Douglas A Lauffenburger; Kevin M Haigis
Journal:  PLoS Biol       Date:  2012-09-25       Impact factor: 8.029

10.  Integrated gut/liver microphysiological systems elucidates inflammatory inter-tissue crosstalk.

Authors:  Wen L K Chen; Collin Edington; Emily Suter; Jiajie Yu; Jeremy J Velazquez; Jason G Velazquez; Michael Shockley; Emma M Large; Raman Venkataramanan; David J Hughes; Cynthia L Stokes; David L Trumper; Rebecca L Carrier; Murat Cirit; Linda G Griffith; Douglas A Lauffenburger
Journal:  Biotechnol Bioeng       Date:  2017-07-27       Impact factor: 4.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.